MedImmune, Micromet begin gastrointestinal cancer drug study

MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen (CEA).

The Phase 1 dose-escalation study is designed to evaluate the safety, tolerability, and antitumour activity of the product candidate in adult patients with advanced gastrointestinal cancers, in which the dose escalation in subsequent cohorts will be based on safety and tolerability.

After the maximum tolerated dose is established, additional study subjects with refractory colorectal or pancreatic cancer will be included in a dose-expansion phase to further assess the safety and antitumour activity.